Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BICO Group ABCLLKF 68 3-Year EPS without NRI Growth Rate is -185.80% as of Jun. 2026. GuruFocus rates CLLKF with a GF Score™ of 68/100 and a GF Value™ of $3.20 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 658 Medical Devices & Instruments companies, BICO Group AB ranks worse than 99.85% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was -185.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -48.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of BICO Group AB was 26.30% per year. The lowest was -349.10% per year. And the median was -185.80% per year.
BICO Group AB (OTCPK:CLLKF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
BICO Group AB 3-Year EPS without NRI Growth Rate Related Terms
CLLKF vs ABT, SYK, MDT: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, BICO Group AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BICO Group AB 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BICO Group AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where BICO Group AB's 3-Year EPS without NRI Growth Rate falls into.
BICO Group AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -185.80% mean?
BICO Group AB (CLLKF) has a 3-Year EPS without NRI Growth Rate of -185.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for BICO Group AB and its competitors. According to the industry distribution chart, BICO Group AB ranks #657 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is BICO Group AB's 3-Year EPS without NRI Growth Rate too high?
BICO Group AB's current 3-Year EPS without NRI Growth Rate is -185.80%. Based on the distribution chart, BICO Group AB ranks #657 out of 658 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BICO Group AB has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BICO Group AB's 3-Year EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BICO Group AB ranks #657 out of 658 companies for 3-Year EPS without NRI Growth Rate. This places BICO Group AB in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for BICO Group AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BICO Group AB's current 3-Year EPS without NRI Growth Rate is -185.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BICO Group AB stock overvalued right now?
Based on GuruFocus' analysis, BICO Group AB (CLLKF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.20, compared to a current price of $2.07 — trading 35.3% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -185.80%. BICO Group AB's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For BICO Group AB (CLLKF), the current 3-Year EPS without NRI Growth Rate is -185.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BICO Group AB (CLLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BICO Group AB stock appears to be undervalued.
The current stock price of $2.07 is trading 35.3% below its estimated GF Value™ of $3.20.
GuruFocus considers BICO Group AB to be Possible Value Trap.
Key valuation signals for CLLKF:
3-Year EPS without NRI Growth Rate: -185.80%
GF Value™: $3.20 vs. price of $2.07 (35.3% below fair value)
No single metric tells the full story. See the CLLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BICO Group AB provides hardware, laboratory automation software, and products to automate and increase efficiency in workflows for pharma and biotech companies. Its portfolio includes automated workstations, lab automation software, microscopes and live-cell imaging, 3D cell culture and bioprinting, single-cell dispensing, liquid handling, mixing technologies, and consumables. The Group operates through two segments: Life Science Solutions, the maximum revenue generator, including CYTENA, DISPENDIX, Discover Echo, QInstruments, SCIENION, Cellenion, CELLINK, and BioMatrix, and Lab Automation, consisting of Biosero, which provides the Green Button Go Suite software and automation integration services.
68GF Score
Get the complete analysis for CLLKF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLLKF has been successfully added to your 
